Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis
Li DH, Sun MW, Zhang JC, Zhang C, Deng L, Jiang H (2021) · Thrombosis Research · n=0
Study Profile
- Design
- systematic review and meta-analysis of 10 studies (9 in meta-analysis): RCTs, cohort, and case-control studies
- Sample size (n)
- 0
- Intervention
- Bivalirudin anticoagulation for ECMO
- Comparator
- Heparin anticoagulation for ECMO
- Primary endpoint
- Hospital mortality, ECMO duration, major bleeding, thrombosis, circuit interventions
- Primary result
- In adults, bivalirudin associated with lower hospital mortality (OR 0.65, 95% CI 0.44-0.95, p=0.03) and lower thrombosis (OR 0.55, 95% CI 0.37-0.83, p=0.004); no significant differences in major bleeding, ECMO duration, or circuit interventions
- Follow-up duration
- Hospital discharge
- PMID
- 35007937
Key Findings
- 35% relative reduction in hospital mortality with bivalirudin in adults
- 45% relative reduction in thrombotic events
- No difference in bleeding, ECMO duration, or circuit interventions
- Authors transparent about low evidence quality
- Complements parallel meta-analyses from Hasegawa, Huang, Wieruszewski
Limitations
- All 10 included studies retrospective observational
- Significant heterogeneity could not be eliminated
- Authors explicitly note low overall evidence level
- Lack of standardization in anticoagulation targets
- Not applicable to whole-leech hirudotherapy
Clinical Implications
Li 2021 provides early systematic review evidence supporting bivalirudin survival and thrombosis benefits in adult ECMO, consistent with parallel syntheses. For ASH, this work demonstrates how aggregated retrospective observational evidence builds the case for the synthetic thrombin inhibitor pharmaceutical pathway, structurally separate from the K040187 device-leech US clinical practice. The author transparency about evidence quality models good methodological practice.
Related Trials
Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation
McMichael A, Weller J, Li X, Hatton L, Zia A, Raman L (2024)
Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support
Trigonis R, Smith N, Porter S, Anderson E, Jennings M, Kapoor R, Hage C, Moiz S, Garcia J, Rahman O (2021)
Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation
Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022)
Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review
Valdes CA, Sharaf OM, Bleiweis MS, Jacobs JP, Mumtaz M, Sharaf RM, Jeng EI, Peek GJ (2023)